Cardiome Reports Positive Oral Vernakalant Data; Says Company Sale Is Possible
This article was originally published in The Pink Sheet Daily
Executive Summary
Canadian firm retains Merrill Lynch to advise on merger and acquisition strategies the same day it reports positive data.
You may also be interested in...
Astellas/Cardiome’s Kynapid “Approvable”
FDA wants more safety data on IV vernakalant.
Astellas/Cardiome’s Kynapid “Approvable”
FDA wants more safety data on IV vernakalant.
New Cash Adds To Cardiome’s Bargaining Chips
Acquisition-hungry big pharma eyes the firm's oral vernakalant, ready for Phase III.